BEDFORD, Mass. (AP) _ Homology Medicines Inc. (FIXX) on Monday reported a loss of $28.2 million in its third quarter.

The Bedford, Massachusetts-based company said it had a loss of 62 cents per share.

The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 81 cents per share.

The gene editing company posted revenue of $567,000 in the period.

Homology Medicines shares have fallen 52% since the beginning of the year. In the final minutes of trading on Monday, shares hit $9.87, a drop of 17% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FIXX at https://www.zacks.com/ap/FIXX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News